| Literature DB >> 31960769 |
Takeshi Aoyama1, Takashi Tsunoda1, Hiroki Kato1, Akane Hagino1, Ryota Furutani1, Kazuyuki Ito1, Hidenori Yoshioka1, Masashi Nakamura1, Makoto Hiraide1, Kazuyoshi Kawakami1, Kazuo Kobayashi1, Kenichi Suzuki1, Takashi Ichimura2, Kensei Yamaguchi2, Toshihiro Hama1.
Abstract
Although a short hydration protocol for cisplatin has been recently developed for use in lung cancer, this has yet to be established for gastric cancer. This study reviewed medical records of patients with gastric cancer who received XPT(capecitabine/cisplatin/trastuzumab) therapy containing cisplatin. Patients received either the conventional or short hydration regimen. Nephrotoxicity was compared between these two regimens by monitoring the serum creatinine. Out of the 26 total patients, 19 received the conventional regimen while 7 received the short hydration regimen. There was a higher nephrotoxicity was observed in the group receiving the conventional regimen (42.1%, 8/19) as compared to the short hydration regimen (0%, 0/7). There was a statistically significant difference in nephrotoxicity between the regimens (P = 0.039). Study results suggest that short hydration may be a feasible regimen for XPT therapy in gastric cancer patients.Entities:
Keywords: Cisplatin; gastric cancer; hydration; magnesium supplementation; nephrotoxicity; short hydration
Mesh:
Substances:
Year: 2020 PMID: 31960769 DOI: 10.1080/1120009X.2020.1713507
Source DB: PubMed Journal: J Chemother ISSN: 1120-009X Impact factor: 1.714